Phase II clinic trial for the reduction of time of haematopoietic stem cell engraftment with sitagliptin in patients with multiple myeloma receiving autologous transplantation.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2012
At a glance
- Drugs Sitagliptin (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Oct 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 07 Jul 2011 New trial record